Ozempic label provides placebo-controlled adverse reaction rates for common events (5%) dominated by GI symptoms (dose-related increases in nausea, vomiting, diarrhoea, constipation/abdominal pain)
Most have been conducted in individuals with type 2 diabetes who were also receiving medications such as metformin, which may independently affect the gut microbiome
Dihydromyricetin protects human umbilical vein endothelial cells from injury through ERK and Akt mediated Nrf2/HO-1 signaling pathway
62 These individual gray matter images were registered to the corresponding calibrated CBF images using inverse transformation
Gallbladder Issues Research shows an increase in gallbladder-related issues in GLP-1 medication users, with conditions ranging from asymptomatic gallstones to severe cholecystitis requiring surgical intervention
Novo Nordisk and Eli Lilly continue to dominate., Although Pfizer discontinued its in-house oral GLP-1 candidate danuglipron in April 2025 following a liver-injury signal, it has doubled back into obesity and GLP-1 with its multi-billion-dollar acquisition of Metsera
